On June 9, Zai Lab announced that tisotumab vedotin (brand name: Tivdak®) was approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed during or after chemotherapy.
Tisotumab vedotin is a first-in-class antibody-drug conjugate (ADC) targeting tissue factor (TF). Non-clinical data indicate that the anti-cancer activity of tisotumab vedotin results from the ADC binding to TF-expressing cancer cells, followed by internalization of the ADC-TF complex and proteolytic cleavage to release monomethyl auristatin E (MMAE). MMAE disrupts the microtubule network of actively dividing cells, leading to cell cycle arrest and apoptotic cell death. In vitro, tisotumab vedotin also mediates antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC).
In September 2022, Zai Lab obtained an exclusive license from Seagen (acquired by Pfizer in 2023) to develop and commercialize tisotumab vedotin in Greater China (Mainland China, Hong Kong, Macao, and Taiwan).
In April 2024, tisotumab vedotin received full approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed during or after chemotherapy.
Results from the global randomized Phase III innovaTV 301 clinical study (NCT04697628) and its Chinese subgroup showed that the Chinese subgroup results were consistent with those of the global population:
- Compared with chemotherapy, tisotumab vedotin reduced the risk of death by 45% (HR: 0.55 [95% CI: 0.27–1.15]) in patients who had received prior standard systemic therapy, with more than half of the Chinese population having received prior anti-PD-(L)1 therapy. After a median follow-up of 11.5 months, the median overall survival (OS) in the tisotumab vedotin group was not reached, while the median OS in the chemotherapy group was 10.7 months.
- Secondary endpoints of progression-free survival (PFS) and confirmed objective response rate (ORR) also favored tisotumab vedotin treatment.
The safety profile of tisotumab vedotin in the Chinese subgroup was manageable and consistent with the global study profile.